India is set to launch the first COVID-19 vaccine by August 15, the Indian Council of Medical Research (ICMR) has confirmed. For the launch of the vaccine, the ICMR has already partnered with Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine). This will be the first indigenous coronavirus vaccine being developed by India and is one of the top priority projects which is being monitored at the topmost level of the government, the ICMR stated in a release.
The vaccine is derived from a strain of SARSCoV-z isolated by tCMR- National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine.
The ICMR has confirmed that India plans to launch its first coronavirus vaccine 'Covaxin' latest by August 15. The ICMR, in this regard, has written a letter to select medical institutions and hospitals to fast-track clinical trial approvals for the vaccine being developed in collaboration with Bharat Biotech.
Twelve clinical trial sites have been identified at present and the apex health research body has asked the medical institutions and principal investigators to ensure that the subject enrolment is initiated no later than July 7.
According to the ICMR, the first coronavirus vaccine for public health will be launched latest by August 15, 2020, once the clinical trials of the vaccine are completed.
The COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.
Noting that this was the first indigenous vaccine being developed by India, ICMR Director-General Dr. Balram Bhargava in his letter to principal investigators of the 12 sites said that it is one of the "top priority projects which is being monitored at the top-most level of the government".
"It is envisaged to launch the vaccine for public health use latest by August 15 after completion of all clinical trials. BBIL is working expeditiously to meet the target, however, the final outcome will depend on the cooperation of all clinical trial sites involved in this project.
"You have been chosen as a clinical trial site of the BBV152 COVID vaccine. In view of the public health emergency due to COVID-19 pandemic and urgency to launch the vaccine, you are strictly advised to fast track all approvals related to the initiation of the clinical trial and ensure that the subject enrolment is initiated no later than July 7," Bhargava said in the letter.
"Kindly note non-compliance will be viewed very seriously. Therefore, you are advised to treat this project on the highest priority and meet the given timelines without any lapse," the letter stated.
A copy of the letter has been sent to the Bharat Biotech.
The final outcome of the vaccine will depend upon the cooperation of all clinical trial sites that are involved with the project, the ICMR stated.
India's COVID-19 cases soared by over 20,000 in a day for the first time taking the country's total tally to 6,25,544 on Friday while the death toll climbed to 18,213 with 379 new fatalities, according to the Union Health Ministry data.
Also Read | Covaxin: India's first coronavirus vaccine by Bharat Biotech to release trial results by Aug 15
Also Read | India's 2nd COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials
